Ribozyme Discovery

Ribozymes are catalytic RNA molecules involved in protein synthesis. Most biological catalysts are enzymes and until around four decades ago, experts believed that only enzymes could serve as catalysts in cells.

In 1967, Carl Woese, Francis Crick, and Leslie Orgel proposed that RNA could in fact perform catalytic functions. They based their suggestion on the finding that RNA could form secondary structures. In the 1980s, the research groups of Thomas Cech and Sidney Altman showed that some catalysts are indeed made of RNA.

Thomas Cech and Sidney Altman went on to win the Nobel Prize in chemistry in 1989 for establishing the catalytic properties of RNA and in 1982, Kelly Kruger and colleagues introduced the term ribozyme in a paper published in the journal Cell.

Cech demonstrated that an intron in the rRNA of protozoans that needed to be removed before the rRNA could function, could excise itself from precursor RNA and carry out an autocatalytic reaction to re-fuse the two ends. Altman demonstrated that RNA from an RNA complex called ribonuclease P cleaves a tRNA precursor, which gives rise to mature tRNA.

Many scientists now believe that at some point in evolution, early forms of life relied on RNA for catalyzing chemical reactions and storing genetic information. This period is sometimes referred to as the “RNA World.” According to the RNA World hypothesis, life forms later evolved to rely on proteins and DNA because in comparison, RNA was less stable and had weaker catalytic capabilities.

The strongest evidence to support the RNA World hypothesis is that the ribosome, which is responsible for building proteins, is in fact a ribozyme. Analysis has shown that although the ribosome is composed of protein, a key mechanism in translation is catalyzed by RNA and not a protein. This supports the theory that earlier life forms would have relied on RNA for chemical reactions and the storage of genetic information.

In addition to providing a better understanding of evolution, the discovery that RNA can act as a biocatalyst is likely to provide a useful tool in gene technology, offering the potential to design defence mechanisms against dangerous infections. Specifically designed ribozymes could potentially be used to shear genes and destroy RNA molecules that give rise to harmful effects in certain organisms. By cutting and destroying virus RNA, for example, an organism could gain protection against viral infections. Gene shearing could also be used to cure the human cold or to create plants that are resistant to viruses. A more challenging application would be the use of gene shears to correct genetic disorders. This would probably require the synthesis of new RNA enzymes and an improved understanding of the mechanisms underlying the catalytic ability of RNA.

Further Reading

Last Updated: Jul 20, 2023

Sally Robertson

Written by

Sally Robertson

Sally first developed an interest in medical communications when she took on the role of Journal Development Editor for BioMed Central (BMC), after having graduated with a degree in biomedical science from Greenwich University.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Robertson, Sally. (2023, July 20). Ribozyme Discovery. News-Medical. Retrieved on July 15, 2024 from https://www.news-medical.net/life-sciences/Ribozyme-Discovery.aspx.

  • MLA

    Robertson, Sally. "Ribozyme Discovery". News-Medical. 15 July 2024. <https://www.news-medical.net/life-sciences/Ribozyme-Discovery.aspx>.

  • Chicago

    Robertson, Sally. "Ribozyme Discovery". News-Medical. https://www.news-medical.net/life-sciences/Ribozyme-Discovery.aspx. (accessed July 15, 2024).

  • Harvard

    Robertson, Sally. 2023. Ribozyme Discovery. News-Medical, viewed 15 July 2024, https://www.news-medical.net/life-sciences/Ribozyme-Discovery.aspx.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.